Transition report pursuant to Rule 13a-10 or 15d-10

Description of Business and Summary of Significant Accounting Policies (Details Narrative)

v3.19.1
Description of Business and Summary of Significant Accounting Policies (Details Narrative)
9 Months Ended 12 Months Ended
Jun. 06, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
Segments
shares
Dec. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
shares
Mar. 31, 2017
USD ($)
Net loss   $ 1,613,972 $ 430,808 $ 735,687  
Net cash used in operating activities   1,028,501 376,023 610,942  
Working capital deficiency   134,236      
Cash equivalents   $ 35,820 $ 23,498 $ 45,833 $ 68,021
Potentially dilutive shares outstanding | shares   3,000,000   3,771,000  
Advertising costs   $ 27,529   $ 21,628  
FDIC uninsured amount   $ 250,000      
Operating segments | Segments   1      
No Customer [Member]          
Concentration risk percentage   10.00%   10.00%  
No Vendor [Member]          
Concentration risk percentage   10.00%   10.00%  
Subsequent to December 31, 2018 [Member]          
Subscription for shares of common stock received   $ 230,365      
Private Placement [Member]          
Number of offering shares of common stock | shares 6,500,000        
Bioanomaly, Inc. [Member]          
Business acquisition number of shares issued | shares 21,908,810        
Shares issued and outstanding percentage 23.00%        
Legal and advisory fees related to merger $ 495,760